Lyka Labs
Lyka Labs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Lyka Labs
Start SIPLyka Labs Investment Rating
-
Master Rating:
-
Lyka Labs has an operating revenue of Rs. 93.07 Cr. on a trailing 12-month basis. An annual revenue de-growth of -51% needs improvement, Pre-tax margin of -14% needs improvement, ROE of -28% is poor and needs improvement. The company has a high debt to equity of 140%, which can be a reason to worry. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 25 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 19 | 17 | 22 | 22 | 28 |
| Operating Expenses Qtr Cr | 17 | 15 | 17 | 16 | 16 |
| Operating Profit Qtr Cr | 3 | 2 | 5 | 6 | 12 |
| Depreciation Qtr Cr | 3 | 3 | 3 | 3 | 9 |
| Interest Qtr Cr | 3 | 3 | 3 | 3 | 3 |
| Tax Qtr Cr | 0 | 0 | 0 | 0 | 13 |
| Net Profit Qtr Cr | -3 | -10 | 0 | 0 | -15 |
Lyka Labs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 2
- Bearish Moving Average
- ___
- 14
- 20 Day
- ₹97.72
- 50 Day
- ₹103.76
- 100 Day
- ₹111.29
- 200 Day
- ₹119.02
- 20 Day
- ₹98.22
- 50 Day
- ₹103.11
- 100 Day
- ₹114.6
- 200 Day
- ₹124
Lyka Labs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹94.7 |
| Second Resistance | ₹96.45 |
| Third Resistance | ₹98.9 |
| RSI | 34.46 |
| MFI | 61.92 |
| MACD Single Line | -3.06 |
| MACD | -3.47 |
| Support | |
|---|---|
| First Resistance | ₹90.5 |
| Second Resistance | ₹88.05 |
| Third Resistance | ₹86.3 |
Lyka Labs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 359,874 | 19,839,854 | 55.13 |
| Week | 285,686 | 14,475,720 | 50.67 |
| 1 Month | 139,366 | 7,704,158 | 55.28 |
| 6 Month | 114,281 | 6,374,590 | 55.78 |
Lyka Labs Result Highlights
Lyka Labs Synopsis
NSE-Medical-Generic Drugs
Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 80.59 Cr. and Equity Capital is Rs. 30.69 Cr. for the Year ended 31/03/2023. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.| Market Cap | 311 |
| Sales | 81 |
| Shares in Float | 1.49 |
| No of funds | 15 |
| Yield |
| Book Value | 3.73 |
| U/D Vol ratio | 0.9 |
| LTDebt / Equity | 83 |
| Alpha | -0.09 |
| Beta | 0.99 |
Lyka Labs
| Owner Name | Apr-23 | Mar-23 | Dec-22 | Sep-22 |
|---|---|---|---|---|
| Promoters | 54.56% | 51% | 47.59% | 47.59% |
| Mutual Funds | 2.69% | 3.31% | 3.54% | 3.54% |
| Insurance Companies | 0.4% | 0.43% | 0.46% | 0.46% |
| Foreign Portfolio Investors | 0.17% | 0.18% | 0.37% | 0.57% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 33.03% | 35.08% | 38.77% | 37.72% |
| Others | 9.15% | 10% | 9.27% | 10.12% |
Lyka Labs Management
| Name | Designation |
|---|---|
| Mr. Kunal N Gandhi | Chairman & M.D & CEO |
| Mr. Yogesh B Shah | Executive Director & CFO |
| Mrs. Nehal N Gandhi | Non Executive Director |
| Mr. Vinod S Shanbhag | Independent Director |
| Mr. Sandeep P Parikh | Independent Director |
| Mrs. Dhara P Shah | Independent Director |
Lyka Labs Forecast
Price Estimates
Lyka Labs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-23 | Audited Results | |
| 2023-04-18 | Others | |
| 2023-02-07 | Quarterly Results | |
| 2023-01-21 | Preferential issue of shares | |
| 2022-11-09 | Quarterly Results |
Lyka Labs FAQs
What is Share Price of Lyka Labs ?
Lyka Labs share price is ₹93 As on 29 May, 2023 | 20:26
What is the Market Cap of Lyka Labs ?
The Market Cap of Lyka Labs is ₹310.7 Cr As on 29 May, 2023 | 20:26
What is the P/E ratio of Lyka Labs ?
The P/E ratio of Lyka Labs is -23.4 As on 29 May, 2023 | 20:26
What is the PB ratio of Lyka Labs ?
The PB ratio of Lyka Labs is 6.8 As on 29 May, 2023 | 20:26